VerastemSTU:2VS +1.89%29 Days Payable is 327.40 as of Mar. 2026, which is 65% below its 10-year median of 930.91. GuruFocus rates STU:2VS with a GF Score™ of 29/100 and a GF Value™ of €38.36 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 700 Biotechnology companies, Verastem ranks better than 76.14% on this metric.
Verastem's average Accounts Payable for the
three
months ended in Mar. 2026 was €9.47 Mil. Verastem's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €2.64 Mil.
Hence, Verastem's Days Payable for the
three
months ended in Mar. 2026 was 327.40.
The historical rank and industry rank for Verastem's Days Payable or its related term are showing as below:
STU:2VS'
s Days Payable Range Over the Past 10 Years
Min: 62.36 Med: 930.91 Max: 6033.36
Current: 412.56
During the past 13 years, Verastem's highest Days Payable was 6033.36. The lowest was 62.36. And the median was 930.91.
STU:2VS's Days Payable is ranked better than 76.14% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs STU:2VS: 412.56
Verastem's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (327.40).
It may suggest that Verastemdelayed paying its suppliers.
Verastem Days Payable Related Terms
Verastem Days Payable Historical Data
* Premium members only.
The historical data trend for Verastem's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2VS vs IRD, PALI, GALT: Days Payable Comparison
For the Biotechnology subindustry, Verastem's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verastem Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verastem's Days Payable distribution charts can be found below:
* The bar in red indicates where Verastem's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Verastem's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verastem (STU:2VS) has a Days Payable of 327.40 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Verastem and its competitors. This is 65% below median its historical median of 930.91. Over the past decade, Verastem's Days Payable has ranged from 62.36 to 6,033.36. According to the industry distribution chart, Verastem ranks #167 out of 700 companies in the Biotechnology industry, placing it in the top 23.9%.
Is Verastem's Days Payable too high?
Verastem's current Days Payable of 327.40 is 65% below median its 10-year median of 930.91. Over the past 10 years, this metric has ranged from a low of 62.36 to a high of 6,033.36. The Biotechnology industry median Days Payable is 113.10. Verastem's value of 327.40 is 189.5% above this industry median. Based on the distribution chart, Verastem ranks #167 out of 700 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Verastem has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verastem's Days Payable compare to IRD and PALI?
According to the Biotechnology industry distribution chart, Verastem ranks #167 out of 700 companies for Days Payable. This places Verastem in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Verastem's value of 327.40 is 189.5% above this benchmark. Historically, Verastem's own Days Payable has ranged from 62.36 to 6,033.36 over the past decade. While the company's 10-year median is 930.91 vs. the industry median of 113.10, Verastem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verastem's current Days Payable of 327.40 is 189.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Verastem and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verastem's current Days Payable is 327.40, which is 65% below median its own 10-year median of 930.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verastem stock overvalued right now?
Based on GuruFocus' analysis, Verastem (STU:2VS) is currently considered Possible Value Trap. The stock's GF Value™ is €38.36, compared to a current price of €3.93 — trading 89.8% below its estimated fair value. The current Days Payable is 327.40, which is 65% below median its 10-year median of 930.91 and 189.5% above the Biotechnology industry median of 113.10. Verastem's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Verastem (STU:2VS), the current Days Payable is 327.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verastem (STU:2VS) Overvalued in 2026?
Based on GuruFocus' analysis, Verastem stock appears to be undervalued.
The current stock price of €3.93 is trading 89.8% below its estimated GF Value™ of €38.36.
GuruFocus considers Verastem to be Possible Value Trap.
Key valuation signals for STU:2VS:
Days Payable: 327.40 (65% below median its 10-year median of 930.91)
GF Value™: €38.36 vs. price of €3.93 (89.8% below fair value)
Industry Position: 189.5% above the Biotechnology median (#167 of 700)
No single metric tells the full story. See the STU:2VS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
29GF Score
Get the complete analysis for STU:2VS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2VS has been successfully added to your 
